A- A A+

The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany. 

Grimmsmann T, Himmel W. 

Eur J Clin Pharmacol. 2021 Jan;77(1):107-115. doi: 10.1007/s00228-020-02948-3. Epub 2020 Aug 17. PMID: 32803292; PMCID: PMC7782395.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782395/

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment. 

Palis H, Marchand K, Peachey GS, Westfall J, Lock K, MacDonald S, Jun J, Bojanczyk-Shibata A, Harrison S, Marsh DC, Schechter MT, Oviedo-Joekes E. 

Subst Abuse Treat Prev Policy. 2021 Sep 16;16(1):68. doi: 10.1186/s13011-021-00399-2. PMID: 34530878; PMCID: PMC8444161.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444161/

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe. 

Siffel C, Page M, Maxwell T, Thun B, Kolb N, Rosenlund M, von Bredow D, Keja J. 

J Child Adolesc Psychopharmacol. 2020 Sep;30(7):439-447. doi: 10.1089/cap.2019.0173. Epub 2020 Apr 21. PMID: 32315539; PMCID: PMC7475084.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475084/

Benzodiazepines and Amphetamines Use among Methadone Maintenance Participants and Their Associations with Treatment Adherence. 

Cheng Z, Diao F, Chen GH, Lin CQ, Li L, Wu ZY, Cao XB.

Biomed Environ Sci. 2021 Jun 20;34(6):499-502. doi: 10.3967/bes2021.069. PMID: 34284859.

http://www.besjournal.com/en/article/doi/10.3967/bes2021.069

Methamphetamine Use and Its Correlates among Individuals with Opioid Use Disorder in a Midwestern U.S. City. 

Daniulaityte R, Silverstein SM, Crawford TN, Martins SS, Zule W, Zaragoza AJ, Carlson RG. 

Subst Use Misuse. 2020;55(11):1781-1789. doi: 10.1080/10826084.2020.1765805. Epub 2020 May 22. PMID: 32441178; PMCID: PMC7473491.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473491/

The Abuse Characteristics of Amphetamine-Type Stimulants in Patients Receiving Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment. 

Liu Y, Liu N, Shen W, Li L, Zhou W, Xu L. 

Drug Des Devel Ther. 2021 May 18;15:2109-2116. doi: 10.2147/DDDT.S305226. PMID: 34040349; PMCID: PMC8140901.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140901/

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report. 

Palis, H., MacDonald, S., Jun, J. et al. 

Harm Reduct J 18, 57 (2021). doi.org/10.1186/s12954-021-00500-9

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-021-00500-9

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. 

Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. 

Nat Med (2021). doi.org/10.1038/s41591-021-01336-3

https://www.nature.com/articles/s41591-021-01336-3

Fatal and non-fatal health incidents related to recreational ecstasy use. 

van Amsterdam J, Pennings E, van den Brink W. 

J Psychopharmacol. 2020 Jun;34(6):591-599. doi: 10.1177/0269881119897559. Epub 2020 Jan 7. PMID: 31909673; PMCID: PMC7249611.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249611/

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database.  

Cohen IV, Makunts T, Abagyan R, Thomas K. 

Sci Rep. 2021 Mar 16;11(1):5997. doi: 10.1038/s41598-021-85389-x. PMID: 33727616; PMCID: PMC7966744.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966744/

Methamphetazine: A Harm Reduction Guide 

(harmreductionactioncenter.org, Denver/USA, 16.06.2018)

https://issuu.com/kat.harm.reduction/docs/methamphetazine.docx

Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis. 

van Amsterdam J, Peters GY, Pennings E, Blickman T, Hollemans K, Breeksema JJJ, Ramaekers JG, Maris C, van Bakkum F, Nabben T, Scholten W, Reitsma T, Noijen J, Koning R, van den Brink W. 

J Psychopharmacol. 2021 Feb 2:269881120981380. doi: 10.1177/0269881120981380. Epub ahead of print. PMID: 33530825.

https://journals.sagepub.com/doi/10.1177/0269881120981380

Crystal Meth: Bupropion plus Naltrexon helfen beim Entzug

Dallas/Texas – Eine Kombination aus dem Opioidantagonisten Naltrexon, der zur Behandlung der Opiat- und Alkoholsucht eingesetzt wird, und dem Antidepressivum Bupropion, das Patienten zum Rauchstop verordnet wird, hat in einer randomisierten Studie im New England Journal of Medicine (2021; DOI: 10.1056/NeJMoa2020214) auch Patienten mit einer Methamphetamin-Abhängigkeit zur Abstinenz verholfen. (aerzteblatt.de, 10.02.2021)

https://www.aerzteblatt.de/nachrichten/120201/Crystal-Meth-Bupropion-plus-Naltrexon-helfen-beim-Entzug

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. 

Sessa B, Higbed L, O'Brien S, Durant C, Sakal C, Titheradge D, Williams TM, Rose-Morris A, Brew-Girard E, Burrows S, Wiseman C, Wilson S, Rickard J, Nutt DJ. 

J Psychopharmacol. 2021 Feb 18:269881121991792. doi: 10.1177/0269881121991792. Epub ahead of print. PMID: 33601929.

https://journals.sagepub.com/doi/10.1177/0269881121991792

Increases in methamphetamine use among heroin treatment admissions in the United States, 2008-17. 

Jones CM, Underwood N, Compton WM. 

Addiction. 2020 Feb;115(2):347-353. doi: 10.1111/add.14812. Epub 2019 Oct 24. PMID: 31503384; PMCID: PMC6982538.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982538/

Alltagsdroge Crystal Meth (Video)

2014 sorgte die Droge "Crystal Meth" für Schlagzeilen, der Stoff wurde plötzlich kiloweise gefunden. Mittlerweile ist die Droge überall, sie gilt als Schmiermittel der Optimierungsgesellschaft. Die Politik? Ignoriert das Thema weitgehend. (Das Erste, 11.01.21, 42:30; Verfügbar bis 11.01.2022)

https://www.daserste.de/information/reportage-dokumentation/dokus/videos/alltagsdroge-crystal-meth-video-100.html

How ecstasy and psilocybin are shaking up psychiatry

Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.  (Nature, News Feature, USA, 27.01.2021)

https://www.nature.com/articles/d41586-021-00187-9

Nora's Blog: ADAPT-2 Trial Results Deliver a Breakthrough in Long Search for Methamphetamine Use Disorder Medication 

The U.S. is facing a surge of overdose deaths involving the use of stimulant drugs, including cocaine and methamphetamine. Multiple drug surveillance systems indicate that methamphetamine is a more pressing danger to public health and safety than opioids in some localities, yet developing medications to treat stimulant use disorders has proven especially challenging. As more patients and providers become familiar with the multiple effective medications now available to treat opioids, the lack of any medication to treat addiction to methamphetamine is increasingly frustrating. That is why the results of a successful multi-site clinical trial of a combined treatment approach for methamphetamine use disorder using two already approved medications, published today in the New England Journal of Medicine, is such important and encouraging news for our field.

(…) a combination of oral bupropion, a commonly prescribed medication used to treat depression and for nicotine cessation, and injectable naltrexone, an opioid antagonist widely prescribed for treating opioid and alcohol use disorders, successfully reduced methamphetamine use and cravings in a large sample of treatment-seeking people with methamphetamine use disorder, compared to placebo. (NIDA, USA, 13.01.2021)

https://www.drugabuse.gov/about-nida/noras-blog/2021/01/adapt-2-trial-results-deliver-breakthrough-in-long-search-methamphetamine-use-disorder-medication

MDMA-assisted psychotherapy for posttraumatic stress disorder: A promising novel approach to treatment. 

Vermetten E, Yehuda R. 

Neuropsychopharmacology. 2020 Jan;45(1):231-232. doi: 10.1038/s41386-019-0482-9. Epub 2019 Aug 27. PMID: 31455855; PMCID: PMC6879520.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879520/

Gray-matter structure in long-term abstinent methamphetamine users. 

Nie L, Zhao Z, Wen X, Luo W, Ju T, Ren A, Wu B, Li J. 

BMC Psychiatry. 2020 Apr 10;20(1):158. doi: 10.1186/s12888-020-02567-3. PMID: 32272912; PMCID: PMC7146984.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146984/

The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. 

Marseille E, Kahn JG, Yazar-Klosinski B, Doblin R (2020) 

PLoS ONE 15(10): e0239997. doi.org/10.1371/journal.pone.0239997

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239997

Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. 

Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. 

Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4. PMID: 32500209; PMCID: PMC7351848.

https://pubmed.ncbi.nlm.nih.gov/32500209/

Distinct neural mechanisms for the prosocial and rewarding properties of MDMA. 

Heifets BD, Salgado JS, Taylor MD, Hoerbelt P, Cardozo Pinto DF, Steinberg EE, Walsh JJ, Sze JY, Malenka RC. 

Sci Transl Med. 2019 Dec 11;11(522):eaaw6435. doi: 10.1126/scitranslmed.aaw6435. PMID: 31826983; PMCID: PMC7123941.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123941/

Medical MDMA Student Educational Slides

MDMA (3,4-Methyl-enedioxy-methamphetamine) was first synthesised in 1912 by chemists at the pharmaceutical company, Merck in Germany. In 1985, MDMA was placed in schedule 1, resulting in no research being conducted into the potential therapeutic applications of MDMA between 1985 – 2000. However, since then, MDMA has been included in over 5000 academic articles and administered to over 1100 human volunteers. (Drug Science, UK, 16.07.2020)

https://drugscience.org.uk/medical-mdma-educational-slides/

Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.

Siefried KJ, Acheson LS, Lintzeris N, Ezard N.

CNS Drugs. 2020 Apr;34(4):337-365. doi: 10.1007/s40263-020-00711-x. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125061/

Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study.

Palmer, A., Scott, N., Dietze, P. et al. 

Harm Reduct J 17, 14 (2020). doi.org/10.1186/s12954-020-00360-9

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-020-00360-9

Methamphetamine use and its impact on violence laid bare in world-first study

Almost a third of middle-aged New Zealanders have tried methamphetamine at least once, according to a new University of Otago, Christchurch study looking at the link between using the drug and violence in the general population. 

The study found those who used methamphetamine at least weekly were between two and five times more likely to be involved in violence, whether it be as a victim or as the perpetrator, than those who had not used it at all. People who had used the drug once or twice were more than 60 percent more likely to be involved in violence during the same time period they were using the drug, compared with non-users. (University of Ontago, Neuseeland, 24.02.2020)

https://medicalxpress.com/news/2020-02-methamphetamine-impact-violence-laid-world-first.html

Using life course charts to assess and compare trajectories of amphetamine type stimulant consumption in different user groups: a cross-sectional study.

Martens MS, Zurhold H, Rosenkranz M, O'Donnell A, Addison M, Spencer L, McGovern W, Gabrhelík R, Petruželka B, Rowicka M, Liebregts N, Degkwitz P, Kaner E, Verthein U.

Harm Reduct J. 2020 Jan 13;17(1):8. doi: 10.1186/s12954-019-0339-x. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956476/

["CrystalClean" - A German-Language Manual for Qualified Detoxification and Motivation Treatment in Cases of "Crystal Meth" Dependency - Feasibility and Acceptance].

Groß C, Schützwohl M, Mayer-Pelinski R, Hasler H, Kirchner T, Scheck A, Behrendt S, Smolka MN, Zimmermann U, Lee NK, Pilhatsch M.

Psychiatr Prax. 2020 Jan;47(1):22-28. doi: 10.1055/a-1003-5148. Epub 2020 Jan 7. German. 

Abstract

https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1003-5148

Clinical effects beyond cocaine use of sustained-release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a double-blind, placebo-controlled randomized trial.

Blanken P, Nuijten M, van den Brink W, Hendriks VM.

Addiction. 2019 Nov 5. doi: 10.1111/add.14874.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31908066